Ir para o conteúdo principal

United States Últimas notícias

Todas as matérias desta categoria, das mais recentes às mais antigas.

Grafa
Health

Vistagen's Phase 3 study of fasedienol for social anxiety disorder fails to meet primary endpoint

Vistagen (NASDAQ:VTGN) announced disappointing results from its PALISADE-3 Phase 3 clinical trial of intranasal fasedienol, a treatment for social anxiety disorder.

The study failed to meet its primary endpoint, which was based on the change from baseline in the Subjective Units of Distress Scale (SUDS).

Leia mais: Vistagen's Phase 3 study of fasedienol for social anxiety disorder fails to meet primary endpoint
Grafa
Health

Traws Pharma reports positive interim data for ratutrelvir

Traws Pharma (NASDAQ:TRAW) reported promising interim results from its Phase 2 trial of ratutrelvir, a ritonavir-free Mpro inhibitor, in the treatment of COVID-19.

The oral treatment, administered at a 600 mg once-daily dose for 10 days, was compared against PAXLOVID™ in a randomized, open-label study involving 37 patients—25 receiving ratutrelvir and 12 receiving PAXLOVID™.

Leia mais: Traws Pharma reports positive interim data for ratutrelvir
Grafa
Health

NorthStrive Biosciences launches Phase III AI development program with Yuva Biosciences

NorthStrive Biosciences (NASDAQ:ELAB) has launched Phase III of its AI Development Program in collaboration with Yuva Biosciences, aiming to validate small-molecule candidates for muscle preservation through mitochondrial function enhancement.

Leia mais: NorthStrive Biosciences launches Phase III AI development program with Yuva Biosciences
Grafa
Health

Cytokinetics announces NMPA approval for MYQORZO in China, triggers milestone payment

Cytokinetics (NASDAQ:CYTK) announced that its drug MYQORZO (aficamten) has received approval from the National Medical Products Administration (NMPA) in China for the treatment of adults with NYHA class II-III obstructive hypertrophic cardiomyopathy.

Leia mais: Cytokinetics announces NMPA approval for MYQORZO in China, triggers milestone payment
Grafa

Steel Dynamics forecasts lower Q4 2025 earnings due to seasonal demand, maintenance outages

Steel Dynamics (NASDAQ:STLD) has provided its earnings guidance for the fourth quarter of fiscal year 2025, forecasting a range of $1.65 to $1.69 per diluted share.

This represents a notable decline from the $2.74 per share earnings reported in the third quarter of 2025, but an increase over the $1.36 per share reported in Q4 2024.

Leia mais: Steel Dynamics forecasts lower Q4 2025 earnings due to seasonal demand, maintenance outages